The Food and Drug Administration has approved the first clinical trial to test a Cuban drug in the United States — a lung-cancer vaccine developed in Havana. The trial will test the CIMAvax-EGF vaccine, combined with an immunotherapy drug called Opdivo, which has already been approved in the United States. Lung cancer is the leading cause of cancer deaths in the United States, with a five-year survival rate of only 17 percent. The studies that have been reported from Cuba are small and have limitations that prevent us from knowing how the treatment could be applied to the typical patient with lung cancer." He added that the history of vaccines in treating cancer has shown many more failures than success.

Source: Washington Post October 27, 2016 11:05 UTC